MELBOURNE - Australian drug developer Bionomics Ltd. has revealed for the first time how its BNC210 compound works to reduce anxiety without the common cognitive side-effects of drugs used to treat panic attacks.
Australia’s Bionomics Unveils Therapeutic Action Of BNC210
Australia’s Bionomics unveils the therapeutic action of its BNC210 compound and faced shareholder questions all in one busy week for the biotech.
More from Focus On Asia
More from Scrip
• By
At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.
• By
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
• By
Vyepti revenues rise by nearly 70% in the first quarter.